[1]任明智,王 涛.西格列汀调节Hippo/Yes相关蛋白信号通路对非小细胞肺癌A549/CDDP细胞增殖、迁移、凋亡与化疗敏感性的影响实验研究[J].陕西医学杂志,2024,(12):1599-1603,1610.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.003]
　REN Mingzhi,WANG Tao.Effects of sitagliptin on proliferation,migration,apoptosis and chemosensitivity of NSCLC A549/CDDP cells by regulating Hippo/YAP signaling pathway[J].,2024,(12):1599-1603,1610.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.003]
点击复制

西格列汀调节Hippo/Yes相关蛋白信号通路对非小细胞肺癌A549/CDDP细胞增殖、迁移、凋亡与化疗敏感性的影响实验研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年12期
页码:
1599-1603,1610
栏目:
基础研究
出版日期:
2024-12-05

文章信息/Info

Title:
Effects of sitagliptin on proliferation,migration,apoptosis and chemosensitivity of NSCLC A549/CDDP cells by regulating Hippo/YAP signaling pathway
作者:
任明智; 王 涛
(空军军医大学第二附属医院胸外科,陕西 西安 710038)
Author(s):
REN Mingzhi; WANG Tao
(Department of Thoracic Surgery,the Second Affiliated Hospital of Air Force Medical University,Xi'an 710038,China)
关键词:
非小细胞肺癌;  西格列汀;  Hippo/Yes相关蛋白信号通路;  化疗敏感性;  细胞增殖;  细胞凋亡;  细胞侵袭
Keywords:
Non-small cell lung cancer;  Sitagliptin;  Hippo/Yes related protein signaling pathway;  Chemosensitivity;  Cell proliferation;  Apoptosis;  Cell invasion
分类号:
R -33
DOI:
DOI:10.3969/j.issn.1000-7377.2024.12.003
文献标志码:
A
摘要:
目的:探究西格列汀(SIT)调节Hippo/Yes相关蛋白(YAP)信号通路对非小细胞肺癌(NSCLC)A549/CDDP细胞增殖、迁移、凋亡和化疗敏感性的影响。方法:常规培养顺铂耐药的NSCLC细胞株A549/CDDP,随机分为对照(Control)组(常规培养)、CDDP组(给予10 μmol/L CDDP)、SIT组(给予10 μmol/L SIT)、CDDP+SIT组(给予10 μmol/L CDDP+10 μmol/L SIT)和CDDP+SIT+YAP激活剂Jasplakinolide(CDDP+SIT+JASP)组(给予10 μmol/L CDDP+10 μmol/L SIT+50 nmol/L JASP)。CCK-8法检测细胞增殖能力,划痕实验检测细胞迁移能力,Transwell实验检测细胞侵袭能力,流式细胞术检测各组细胞凋亡率,实时荧光定量PCR(RT-qPCR)检测细胞YAP mRNA表达水平,Western blot检测Hippo/YAP信号通路相关蛋白与B细胞淋巴瘤-2(Bcl-2)、Bcl-2相关X蛋白(Bax)表达水平。结果:与Control组比较,CDDP组和SIT组OD450值(48、72 h)、细胞侵袭数目、细胞迁移率、YAP mRNA水平及YAP、Bcl-2蛋白表达下降,细胞凋亡率、磷酸化YAP(p-YAP)和Bax蛋白表达及哺乳动物STE20样激酶1/2(MST1/2)、大肿瘤抑制激酶1/2(LATS1/2)的磷酸化水平增高(均P<0.05)。与CDDP组比较,CDDP+SIT组上述指标趋势增强(均P<0.05)。与CDDP+SIT组比较,CDDP+SIT+JASP组减弱了SIT对A549/CDDP细胞化疗敏感性的提高。结论:SIT能够促进A549/CDDP细胞凋亡,抑制细胞迁移、侵袭和增殖,提高A549/CDDP细胞化疗敏感性,其机制可能与激活Hippo/YAP信号通路有关。
Abstract:
Objective:To investigate the effects of sitagliptin(SIT)on the proliferation,migration,apoptosis and chemosensitivity of non-small cell lung cancer(NSCLC)A549/CDDP cells by regulating the Hippo/Yes-associated protein(YAP)signaling pathway.Methods:The cisplatin resistant NSCLC cell line A549/CDDP was routinely cultured and randomly grouped into Control group(conventional culture),CDDP group(treated with 10 μmol/L CDDP),SIT group(treated with 10 μmol/L SIT)and CDDP+SIT group(treated with 10 μmol/L CDDP+10 μmol/L SIT),CDDP+SIT+YAP activator Jasplakinolide(CDDP+SIT+JASP)group(treated with 10 μmol/L CDDP+10 μmol/L SIT+50 nmol/L JASP).CCK-8 method was applied to detect cell proliferation.Scratch experiment was applied to detect the ability of cellsmigration.Transwell experiment was applied to detect the invasiveness of cells.The rate of apoptosis was detected by flow cytometry.The expression level of YAP mRNA was detected by RT-qPCR.Western blot was applied to detect the expression levels of cell Hippo/YAP signaling pathway related proteins and apoptosis related proteins Bcl-2 and Bax.Results:Compared with the Control group,the OD450 value(48 and 72 hours),cell migration rate,cell invasion number,YAP mRNA expression,YAP and Bcl-2 protein expressions of A549/CDDP cells in the CDDP group and SIT group were decreased,the apoptosis rate,expressions of p-YAP,Bax,p-MST1/2 and p-LATS1/2 protein were increased(all P<0.05).Compared with the CDDP group,the above indexes in the CDDP+SIT group showed an enhanced trend(all P<0.05).Compared with CDDP+SIT group,CDDP+SIT+JASP group attenuated the enhancement of chemosensitivity of A549/CDDP cells induced by SIT.Conclusion:SIT can promote apoptosis of A549/CDDP cells,inhibit cell migration,invasion and proliferation,and increase chemotherapy sensitivity of A549/CDDP cells,the mechanism may be related to the activation of Hippo/YAP signaling pathway.

参考文献/References:

[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] 李晶,苏帆,林芷伊,等.PDCD5蛋白基于顺铂为基础的非小细胞肺癌化疗敏感性[J].中国老年学杂志,2020,40(16):3499-3503.
[3] HOWLADER N,FORJAZ G,MOORADIAN M J,et al.The effect of advances in lung-cancer treatment on population mortality[J].N Engl J Med,2020,383(7):640-649.
[4] WANG X W,GUO Q Q,YU Y,et al.The deacetylation of Foxk2 by Sirt1 reduces chemosensitivity to cisplatin[J].J Cell Mol Med,2022,26(2):491-506.
[5] ZHU P,WANG L,XU P,et al.GANT61 elevates chemosensitivity to cisplatin through regulating the Hedgehog,AMPK and cAMP pathways in ovarian cancer[J].Future Med Chem,2022,14(7):479-500.
[6] NARGIS T,CHAKRABARTI P.Significance of circulatory DPP4 activity in metabolic diseases[J].IUBMB Life,2018,70(2):112-119.
[7] HEMATYAR J,RASHIDI H,ZAKERKISH M,et al.Effect of sitagliptin versus glibenclamide on glycemic markers,lipid profile inflammatory and oxidative stress factors in type 2 diabetes patients:A double-blinded randomized controlled trial[J].Maedica(Bucur),2022,17(4):762-770.
[8] CHENG S Y,WU A T H,BATIHA G E,et al.Identification of DPP4/CTNNB1/MET as a theranostic signature of thyroid cancer and evaluation of the therapeutic potential of sitagliptin[J].Biology(Basel),2022,11(2):324-335.
[9] 杨忠英,岳德永,程凤姣.复方斑蝥胶囊对肝癌细胞Hippo/YAP通路及血管生成拟态的影响[J].中国药师,2021,24(11):1983-1986,1992.
[10] SHAN L,JIANG H,MA L,et al.Yes-associated protein:A novel molecular target for the diagnosis,treatment and prognosis of hepatocellular carcinoma[J].Oncol Lett,2017,14(3):3291-3296.
[11] 李志瀚,雷蕾,郑艺雯,等.TRIP13通过Hippo信号通路促进非小细胞肺癌的增殖、迁移和侵袭[J].解剖科学进展,2022,28(4):487-490,494.
[12] 邵莎莉,庄喜兵,乔田奎.氟西汀通过p21相关通路增加顺铂对非小细胞肺癌细胞株的抗肿瘤作用[J].复旦学报(医学版),2023,50(1):48-56.
[13] 张玫,李进冬,凌亚.基于TGF-β1/AKT信号通路的西格列汀对人肾小管上皮细胞转化的干预及机制[J].临床与病理杂志,2020,40(5):1087-1092.
[14] 韩潇.Hippo信号通路在宫腔粘连、薄型子宫内膜中的作用及机制研究[D].郑州:郑州大学,2021.
[15] LI W C,WANG Z,GAO J,et al.Clinical outcomes and prognostic factors of salvage stereotactic body radiotherapy for post-surgical thoracic oligo-recurrence/metastasis of non-small-cell lung cancer[J].Cancer Manag Res,2021,13(1):1887-1896.
[16] 吴皞,薛维伟,陈雪,等.疏肝健脾法对非小细胞肺癌患者化疗期间肿瘤标志物的影响[J].陕西中医,2024,45(7):905-908.
[17] VASAN N,BASELGA J,HYMAN D M.A view on drug resistance in cancer[J].Nature,2019,575(7782):299-309.
[18] WU X,ZHONG Y,CHEN Q,et al.Enhancer of mRNA decapping protein 4(EDC4)interacts with replication protein a(RPA)and contributes to cisplatin resistance in cervical cancer by alleviating DNA damage[J].Hereditas,2020,157(1):41-49.
[19] 周家香,吴春芝,冯芳,等.康莱特静脉注射联合顺铂灌注对晚期非小细胞肺癌患者免疫功能和肿瘤标志物的影响[J].陕西医学杂志,2024,53(6):818-822.
[20] WENJING H,SHUANG Y,WEISONG L,et al.Exendin-4 does not modify growth or apoptosis of human colon cancer cells[J].Endocr Res,2017,42(3):209-218.
[21] KOSOWSKA A,GARCZORZ W,KLYCH-RATUSZNY A,et al.Sitagliptin modulates the response of ovarian cancer cells to chemotherapeutic agents[J].Int J Mol Sci,2020,21(23):8976-8989.
[22] 陆攀,孟欣,王彪,等.西格列汀抑制膀胱癌细胞增殖和诱导细胞凋亡[J].解剖科学进展,2020,26(1):44-46,50.
[23] VARELA-CALVIÑO R,RODRÍGUEZ-QUIROGA M,CARVALHO D P,et al.The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities[J].IUBMB Life,2021,73(5):761-773.
[24] IBAR C,IRVINE K D.Integration of Hippo-YAP signaling with metabolism[J].Dev Cell,2020,54(2):256-267.
[25] GU Y,DING C,YU T,et al.SIRT7 promotes Hippo/YAP activation and cancer cell proliferation in hepatocellular carcinoma via suppressing MST1[J].Cancer Sci,2024,115(4):1209-1223.
[26] 孟祥彩,刘洋,武玉,等.黄芩素在伊立替康抑制结肠癌细胞增殖中的作用研究[J].陕西中医,2022,43(12):1682-1685.
[27] 祝景伟,佟经伟,许培权.Hippo信号通路中TAZ、YAP在三阴性乳腺癌中的表达及意义[J].陕西医学杂志,2020,49(8):940-943,968.
[28] WANG Q,LU P,WANG T,et al.Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma-associated antigen-A3 expression through Yes-associated protein inactivation[J].Cancer Med,2020,9(11):3816-3828.

相似文献/References:

[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
　PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(12):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[3]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
　YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(12):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[4]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[5]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
　SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(12):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
　CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(12):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[8]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
　CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(12):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[9]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
　CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(12):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[10]梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
　LIANG Lele,WANG Peng,LIU Junxia,et al.Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer[J].,2021,50(12):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(S2021-YF-YBSF-0592)
更新日期/Last Update: 2024-12-05